TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumorsRuth Plummer, Nagy Habib, David J. Pinato et al.|Cell Reports Medicine|2025Cited by 12
Abstract CT094: Phase I dose-escalation study evaluating the safety and tolerability of ginisortamab (UCB6114), a first-in-class anti-gremlin-1 monoclonal antibody (mAb), as monotherapy in advanced solid tumorsDebashis Sarker, Udai Banerji, Leonidas Mavroeidis et al.|Cancer Research|2023Cited by 6